arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

BIOLIFE SOLUTIONS INC

BLFS
$34.63 ▲ +0.71 (+2.09%) at close
Healthcare ·Electromedical & Electrotherapeutic Apparatus ·USElectromedical & Electrotherapeutic Apparatus
17 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
39
Health
Weak
Neutral
auto_awesome

Analytical Summary

BIOLIFE SOLUTIONS INC shows mixed fundamentals. On the positive side, Debt to Equity remains strong. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $1.7B
Dividend Yield
Revenue Growth 28.9%
Op. Margin -17.3%
ROIC -4.4%
FCF / Share $0.22
Trailing P/E
Price / Book 4.5x
FCF Yield 0.6%
Debt / Equity 0.01
info Valuation on last close. End-of-day price, Aug 7, 2026.

17-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$96.21M
↑ +28.9%
Net Income Profit after all expenses
$-4.59M
↑ +77.2%
Operating Margin Operating profit as % of sales
-17.3%
↓ -187.7% 11th
FCF / Share Free cash flow per share
$0.22
↑ +97.2%
Long-Term Debt Long-term obligations
$5.00M
↓ -68.7%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
33
Returns
42
Financial Health
58
Cash Quality
6

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 17 years · 66 quarters